Monoclonal Antibody Market Size, Share, Competitive Landscape and Trend Analysis Report by Source, by Production, by Indication and by End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

Monoclonal antibodies are replicas of a unique parental cell derived from identical immune cells. These antibodies can bind to a particular antigen when administered, as they have monovalent affinity. Monoclonal antibodies serve as an important tool to detect or purify substances, owing to their site specificity; thus, they have important end use in biochemistry, molecular biology, and medicine.

Growth in demand for personalized medicines and surge in development of therapeutic antibodies drives the monoclonal antibodies market. Moreover, advantages such as homogeneity, specificity, and large-scale production; and fewer side effects related to substitute drugs are expected to boost the market growth. However, high cost of R&D activities and expensive treatment options of monoclonal antibodies may restrain this growth.

The global monoclonal antibody market is segmented based on source, production, indication, end user, and region. Based on source, it is classified into murine, chimeric, humanized, and human. Based on production, it is divided into in vivo and in vitro. Based on indication, it is segmented into cancer, autoimmune diseases, inflammatory diseases, infectious diseases, microbial diseases, and others. The end user includes hospitals, research institutes, and others. Based on region, it is analyzed across North America, Europe, Asia Pacific, and LAMEA. These regions are further analyzed across the country level to determine the market size and forecast for each segment and sub-segment.

Comprehensive competitive analysis and profiles of major players, such as Pfizer, Inc., GlaxoSmithKline plc, Novartis AG, Merck & Co. Inc, Amgen Inc., Abbott Laboratories, AstraZeneca, Eli Lilly and Company, Mylan N.V., and Daiichi Sankyo Company, Ltd., are provided in this report.

Key Benefits

• The study provides an in-depth analysis, current trends, and future estimations of the global monoclonal antibody market to elucidate the imminent investment pockets.
• Extensive analysis is conducted by following key player positioning and monitoring the top competitors within the market framework.
• It offers a quantitative analysis to enable the stakeholders to capitalize on the prevailing market opportunities.
• Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
• Key players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.

  Monoclonal Antibody Market Report Highlights

Aspects	Details
By Source	Murine Chimeric Humanized Human
By Production	In Vivo In Vitro
By Indication	Cancer Autoimmune Diseases Inflammatory Diseases Infectious Diseases Microbial Diseases Others
By End User	Hospitals Research Institutes Others
By Region	North America  (U.S., Canada, Mexico) Europe  (France, Germany, Italy, Spain, UK, Rest of Europe) Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific) LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players	AstraZeneca, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Merck and Co. Inc, Abbott Laboratories, Daiichi Sankyo Company, Ltd., Mylan N.V., Pfizer, Inc., Eli Lilly and Company